What is pemvidutide, and what makes its GLP-1/glucagon profile different?

The short answer

Pemvidutide is Altimmune's investigational GLP-1/glucagon dual receptor agonist for obesity and fatty-liver disease (MASH). In Phase 2, it produced about 15.6% weight loss at 48 weeks — and stood out for preserving lean (muscle) mass unusually well, with roughly 78% of the weight lost coming from fat. It also resolved MASH in over half of patients. It has FDA Fast Track status for MASH but is not approved.

Evidence tier: Tier 1 for the published/announced Phase 2 results; Tier 2 for cross-trial comparisons. Educational content, not medical advice.

The key points:

• GLP-1 + glucagon dual agonist (same class as survodutide)
• ~15.6% weight loss at 48 weeks (Phase 2 MOMENTUM, 2.4 mg)
• Standout: lean-mass preservation — most of the loss was fat, not muscle
• MASH: resolved in ~52–59% of patients; FDA Fast Track; not approved

For the drug-class background, see the GLP-1 complete guide.

What is pemvidutide?

Evidence tier: 2 — established pharmacology.

Pemvidutide is an investigational, peptide-based GLP-1 and glucagon receptor dual agonist from Altimmune, in development for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). Like survodutide, it pairs the appetite-suppressing GLP-1 pathway with glucagon-receptor activation — and the glucagon arm is doing the distinctive work. Glucagon increases energy expenditure and acts directly on the liver to mobilize and reduce hepatic fat, which is why GLP-1/glucagon agonists are being pursued for liver disease as well as weight (survodutide, the other GLP-1/glucagon agonist).

The U.S. FDA has granted pemvidutide Fast Track designation for MASH, reflecting both the unmet need in that condition and the strength of the early data. As an investigational peptide, it's delivered by weekly subcutaneous injection. What separates pemvidutide from the crowd isn't the receptor combination itself — survodutide shares it — but a specific feature of its body-composition data: it appears to spare muscle during weight loss to a notable degree. That single finding is much of why the drug is interesting, and it connects directly to one of the biggest real-world worries about GLP-1 weight loss.

Why is pemvidutide's "lean mass preservation" a big deal?

Evidence tier: 1–2 — Phase 2 MRI sub-study.

One of the genuine downsides of rapid GLP-1 weight loss is that a meaningful fraction of the weight lost is lean mass — muscle — not just fat. Losing muscle matters for strength, metabolic rate, and healthy aging, and it's a leading reason people pair GLP-1s with resistance training and adequate protein (and why drugs that protect muscle are of such interest). In an MRI body-composition sub-study of the Phase 2 obesity trial, pemvidutide's lean loss ratio was about 21.9% — meaning roughly 78% of the weight lost was fat and only about 22% was lean tissue. That's a favorable ratio compared with what's often seen, and it's why the result was described as potentially class-leading.

The plausible mechanism is, again, the glucagon arm: glucagon's metabolic effects may bias weight loss toward fat and help maintain lean tissue. If this body-composition advantage holds up in larger trials, it could be pemvidutide's real differentiator in a crowded field — not "more weight loss," but "better-quality weight loss." That said, this is a Phase 2 sub-study in a modest number of participants, and body-composition findings need confirmation at scale before anyone should treat muscle preservation as an established benefit. It's also worth noting that good lifestyle practices — adequate protein intake and resistance training — improve the fat-to-lean loss ratio with any GLP-1 drug, so a drug-level advantage would add to, not replace, those habits. For the broader muscle-loss question across the class, see GLP-1 muscle preservation.

How much weight does pemvidutide cause people to lose?

Evidence tier: 1 — Phase 2 randomized trial.

The headline obesity data come from the 48-week Phase 2 MOMENTUM trial (391 adults with obesity or overweight plus a comorbidity, without diabetes; ClinicalTrials.gov NCT04881760). Mean weight loss reached 10.3%, 11.2%, and 15.6% at the 1.2 mg, 1.8 mg, and 2.4 mg doses respectively, versus 2.2% on placebo. At the top dose, over 50% of participants lost at least 15% of body weight and over 30% lost at least 20% — a solid result that places pemvidutide firmly among the effective next-generation agents, even if its peak number sits a little below the very highest performers.

It's worth noting the trajectory and the dose-response were clean, and the drug's appeal is less about topping the leaderboard on raw weight loss and more about the combination of competitive weight loss plus the favorable body-composition profile. As with every drug at this stage, these are Phase 2 results over 48 weeks; the durability, the full magnitude, and the safety picture over longer, larger Phase 3 trials all remain to be established. The numbers are real and encouraging — they're simply not yet confirmatory.

What about MASH (fatty liver disease)?

Evidence tier: 1 — Phase 2b randomized trial, with mixed reception.

Pemvidutide's liver program is central to its story. In the Phase 2b IMPACT trial in patients with biopsy-confirmed MASH and fibrosis (stage F2–F3; ClinicalTrials.gov NCT05989711), 24-week results showed MASH resolution without worsening of fibrosis in about 59.1% (1.2 mg) and 52.1% (1.8 mg) of patients, versus 19.1% on placebo (Lancet, IMPACT 24-week results). An earlier randomized study had already shown pemvidutide reduces liver fat in MASLD (PMID 39002641). On the resolution endpoint, those are strong numbers.

Here's the honest nuance: the market reaction to the MASH data was mixed, because in MASH the harder, more meaningful endpoint is often fibrosis improvement (reversing scarring), not just inflammation resolution — and the fibrosis signal at 24 weeks was less clear-cut than the resolution numbers. Later 48-week data showed improvements in non-invasive fibrosis markers (such as ELF and liver stiffness), which Altimmune framed as success, but the degree to which pemvidutide reverses established fibrosis remains the key question the Phase 3 program will need to answer. So the MASH picture is genuinely promising on disease resolution, with the fibrosis question still open — a fair, evidence-led reading rather than the unqualified win the headlines sometimes imply.

How does pemvidutide compare to survodutide and the pipeline?

Evidence tier: 2 — cross-trial comparison, not head-to-head.

Pemvidutide and survodutide are the two prominent GLP-1/glucagon agonists, so they're natural comparators — both target obesity and MASH through the same receptor pair. In cross-trial terms, survodutide has shown somewhat higher peak weight loss, while pemvidutide's distinguishing claim is its lean-mass preservation; head-to-head, neither has been tested against the other. Against the wider field — tirzepatide and VK2735 (GLP-1/GIP), amycretin (GLP-1/amylin), MariTide (GLP-1 + GIP-antagonist), retatrutide (triple agonist) — pemvidutide is a mid-pack performer on raw weight loss that competes on quality of weight loss and liver benefit (next-gen multi-agonists overview).

The universal caveat applies: these are cross-trial comparisons, not head-to-head trials, so the rankings are suggestive, not definitive. The fair summary is that pemvidutide is a credible next-generation contender whose case rests on a specific, differentiated profile — competitive weight loss, notably good muscle preservation, and a serious MASH program with Fast Track status — rather than on being the single most powerful agent. Whether that profile wins a place in the market depends on Phase 3 confirming both the body-composition advantage and the liver benefits.

Limitations

This is educational content, not medical advice.

• Efficacy data are Phase 2/2b — promising, but durability and full effect await Phase 3.
• Lean-mass preservation comes from a Phase 2 MRI sub-study — encouraging but needs confirmation at scale.
• The MASH fibrosis question is still open — resolution data are strong; fibrosis reversal is less settled.
• Cross-trial comparisons aren't head-to-head — don't directly rank pemvidutide vs survodutide numbers.
• Not approved anywhere — online "pemvidutide" is gray-market and not genuine.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Pemvidutide is Altimmune's GLP-1/glucagon dual agonist, and its case is built on profile rather than peak numbers: roughly 15.6% weight loss at 48 weeks in Phase 2, with a standout body-composition result — most of the weight lost was fat, not muscle — plus strong MASH-resolution data and FDA Fast Track status for liver disease. The open questions are whether the lean-mass advantage and the liver-fibrosis benefits hold up in Phase 3. It's investigational and not approved, so anything sold online as "pemvidutide" is fake. For anyone tracking the next wave of metabolic drugs, it's a differentiated contender worth watching — particularly if preserving muscle during weight loss matters to you.

Related on this site

• GLP-1 complete guide
• Survodutide (glucagon/GLP-1) explained
• Next-gen multi-agonists overview
• GLP-1 muscle preservation
• Managing GLP-1 side effects
• Our evidence-tier framework

References

• Safety and efficacy of weekly pemvidutide versus placebo for MASH (IMPACT): 24-week results from a phase 2b study. Lancet 2025. doi:10.1016/S0140-6736(25)02114-2 — Phase 2b MASH resolution data.
• Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. PMID 39002641 — liver-fat reduction.
• MOMENTUM Phase 2 obesity trial of pemvidutide. ClinicalTrials.gov NCT04881760 — 48-week obesity efficacy and body composition.